OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Purchases 280,183 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 280,183 shares of OPKO Health stock in a transaction dated Friday, November 8th. The shares were bought at an average price of $1.50 per share, with a total value of $420,274.50. Following the transaction, the chief executive officer now directly owns 211,512,405 shares in the company, valued at approximately $317,268,607.50. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OPKO Health Price Performance

NASDAQ:OPK traded up $0.07 during trading hours on Friday, hitting $1.52. The company’s stock had a trading volume of 5,926,202 shares, compared to its average volume of 6,999,037. OPKO Health, Inc. has a 52-week low of $0.85 and a 52-week high of $1.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The business’s 50-day moving average is $1.52 and its two-hundred day moving average is $1.42. The company has a market capitalization of $1.06 billion, a PE ratio of -4.58 and a beta of 1.65.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. The company had revenue of $182.20 million during the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The firm’s quarterly revenue was down 31.3% compared to the same quarter last year. During the same period last year, the company posted ($0.03) earnings per share. As a group, research analysts anticipate that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th. Piper Sandler restated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday. Finally, StockNews.com upgraded shares of OPKO Health to a “sell” rating in a research report on Saturday, July 27th.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc boosted its position in OPKO Health by 79.1% during the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of OPKO Health during the first quarter worth $26,000. Algert Global LLC acquired a new position in OPKO Health in the second quarter valued at $44,000. Private Advisor Group LLC lifted its position in OPKO Health by 242.7% during the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after buying an additional 25,000 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in OPKO Health in the 1st quarter worth about $47,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.